Journal article
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
Abstract
BACKGROUND: Multiple myeloma is a malignant plasma cell disorder characterised by clonal plasma cells that cause end-organ damage such as renal failure, lytic bone lesions, hypercalcaemia and/or anaemia. People with multiple myeloma are treated with immunomodulatory agents including lenalidomide, pomalidomide, and thalidomide. Multiple myeloma is associated with an increased risk of thromboembolism, which appears to be further increased in …
Authors
Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H
Journal
Cochrane Database of Systematic Reviews, Vol. 2023, No. 9,
Publisher
Wiley
DOI
10.1002/14651858.cd014739
ISSN
1361-6137